Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer
NCT ID: NCT03915171
Last Updated: 2019-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2019-03-01
2020-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer
NCT07312500
Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test
NCT06943768
Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy
NCT04032353
Computational Prediction and Experimental Validation of Gastric Cancer Associated Neoantigens
NCT05498194
Fecal Helicobacter Pylori Gene Detection for Gastric Cancer
NCT06943781
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MSI-H
IHC/PCR tested as dMMR/ MSI-H
Next generation sequencing
NGS can provide genetic and MSI test for patients
MSS
IHC/PCR tested as pMMR/ MSS
Next generation sequencing
NGS can provide genetic and MSI test for patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Next generation sequencing
NGS can provide genetic and MSI test for patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically diagnosed as gastric cancer, duodenal cancer or small intestinal cancer (stage III, stage IV).
* The status of dMMR/pMMR was confirmed by IHC/PCR.
* with tissue and blood samples (including ctDNA and white blood cells) that meet the requirements.
* Agree to provide demographic, medical history, pathological diagnosis, imaging diagnosis, TNM staging, ECOG score and other information.
Exclusion Criteria
* Others that the investigator consider that is inappropriate for this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Medical University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yunpeng Liu
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yunpeng Liu, Ph.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSTL2018011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.